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Shiga-like toxin-producing Escherichia coli (STEC) O157:H7 poses grave challenges to
public health by its ability to cause severe colonic diseases and renal failure in both
human and animals. Shiga-like toxins are the major pathogenic factor for some highly
virulent E. coli expecially Shiga-like toxin 2. Conventional treatments such as antibiotics
can facilitate the release of the toxin thus potentially exacerbate the diseases. Small
molecule inhibitors and antibodies capable of neutralizing the toxins are the two major
venues for the development of therapeutics against enterohemorrhagic serotype E. coli
infection. While promising and potentially effective at clinical settings, these approaches
need to overcome obstacles such as the limited routes of administration, responses
from the host immune system, which are known to differ greatly among individuals. Our
previous studies demonstrate that Baicalin (BAI), a flavonoid compound isolated from
Scutellaria baicalensis protects against rStx2-induced cell cytotoxicity and also protects
mice from lethal rStx2 challenges by inducing Stx2 to form inactive oligomers. In this
manuscript, we present some exciting work showing that baicalin is an effective agent
for therapeutic treatment of STEC O157:H7 infection.
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INTRODUCTION
Infection by the enterohemorrhagic serotype Escherichia coli (EHEC) O157:H7 leads to clinical
symptoms ranging from watery or bloody diarrhea to the life-threatening hemolytic-uremic
syndrome (HUS) associated with kidney failure in both human and animal hosts, such as
greyhound dogs (Gerber et al., 2002). Cattle and sheep are among the most important reservoir
hosts of this pathogen (Raya et al., 2006; Jaros et al., 2016). EHEC infection is a leading cause
of these diseases. For example, in the United States, about 36% of the 265,000 STEC infections
are caused by strain O157:H7 (Zama and Fariza, 2014). Infection by E. coli O157:H7 often occurs
following the consumption of contaminated food or drink. The bacterium is highly virulent; a
low infectious dose in the range of 10 to 100 colony-forming units (CFU) is sufficient to cause
successful infections (Buchanan and Edelson, 1996). Shiga toxins (Stx) expressing from a prophage
are considered the single most important virulence factor of this group of pathogenic E. coli
(O’Brien et al., 1992). Strains expressing Stx2 alone are more virulent than those that express both
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Stx1 and Stx2 (Ostroff et al., 1989). Furthermore, Stx2 is about
1000 times more toxic than Stx1 (Louise and Obrig, 1995). Thus,
Stx2 plays a dominant role in the pathogenicity of STEC.
Treating infections caused by E. coli O157:H7 has been
historically challenging. The usefulness of traditional antibiotics
in the treatment of HUS has been a subject of debate. Because
of the potential induction of the production and release of the
Stx by antimicrobial agents, chemotherapy is not recommended
for patients with diarrhea caused by O157:H7 or E. coli
elaborating similar toxins (Wong et al., 2000). For example,
antibiotics of the quinolone family stimulate Stx production
by E. coli O157:H7, the transfer of the prophage and more
deaths (Zhang et al., 2000). As a result, several alternative
therapeutic strategies have been developed. Among these, the
use of analogs of Gb3, the receptor of Stx to block the
recognition of the toxin by the cells (Nishikawa et al., 2005)
and monoclonal antibodies that specifically neutralize the toxins
(Yamagami et al., 2001) has gained considerable success in
animal models. Similarly, a recent study showed that Retro-2cycl,
a synthetic inhibitor for retrograde trafficking of mammalian
cells is effective in protecting mice from lethal infections by
E. coli O104:H4 (Secher et al., 2015). While promising and
potentially effective at clinical settings, these approaches need to
overcome obstacles such as the limited routes of administration,
responses from the host immune system, which are known
to differ greatly among individuals. For agents such as Retro-
2cycl that directly targets an essential host cellular process,
its potential (detrimental) effects warrant further evaluation.
These limitations have urged the development of novel effective
therapeutics that is low-cost, easy to use and known of low
toxicity.
Our previous studies demonstrate that Baicalin (BAI), a
flavonoid compound isolated from Scutellaria baicalensis protects
mice from lethal Stx2 challenges by inducing Stx2 to form inactive
oligomers (Dong et al., 2015). Here, we extended our study on the
protective effects of BAI in the treatment of O157:H7 infections
in both tissue culture and a mouse model that mimics clinical
outcomes. Our results show that BAI is a potentially useful
compound in treating O157:H7 infections caused by its natural
route of infection.
MATERIALS AND METHODS
Mitomycin C (MMC) treatment is known to induce the
production of Stx toxins, particularly Stx2, leading to
exacerbation of the disease symptoms (Fujii et al., 1994);
we thus first determined the effects of this agent on the
production of Stxs by O157:H7 strain EDL933 (Miranda et al.,
2004). A sub-inhibitory concentration (100 ng/ml) of MMC
was added to cultures of strain EDL933 for 14 h; bacterium-free
culture supernatant obtained from the cultures was incubated
with Hela cells.
We next evaluated the protection effects of BAI on mice
infected with O157:H7 strain EDL933 (ATCC 43895). All animal
studies were performed according to the regulations for the
Administration of Affairs Concerning Experiments Animals
(1988.11). The experimental protocols were approved and
supervised by the Institutional Animal Care and Use Committee
of Jilin University.
BALB/c mice of 8-week age weighing between 16 and
18 g obtained from the Experimental Animal Center of Jilin
University (Changchun, China) were given streptomycin (5 g/L
in water) ad libitum for 3 days to disrupt their normal intestinal
flora (Fujii et al., 1994). On day 3, mice were starved for 6 h
prior to infection. For mortality study, 15 mice in each group
were challenged with 1.5 × 108 cfu/200µl bacterial suspension
through orally administration simultaneously with a single
dose of MMC (2.5 mg/kg of body weight) by intraperitoneal
injection. As controls, mice not treated with MMC were
similarly inoculated with identical bacterial suspensions. At
24 h post–inoculation, BAI was given to the infected mice
through the oral route at 100 mg per kg of body weight, and
then at 8-h intervals for an additional 5 days (Supplementary
Table S1).
We also determined the ability of BAI in protecting against
the weight loss caused by sub-lethal infections by EDL933. BAI
alone at a dose as high as 100 mg/kg did not detectably affect
mouse body weight over a 10-day period (Dong et al., 2015). In
our experiments here, mice inoculated with PBS or with a single
dose of O157:H7 (7.5× 107 per mouse) were monitored for body
weight at 24-h intervals. BAI was given at 100 mg/kg 24-h after
infection and then at 8-h intervals for 10 days (Supplementary
Table S2).
Next, we evaluated the effects of BAI treatment in alleviating
renal injuries caused by O157:H7 infection. Mice infected with
7.5 × 107 cfu together with MMC were either treated with BAI
as described above or with PBS. At 6-day post-infection, kidneys
from mice of different experimental groups were sectioned for
pathological examination (Supplementary Table S2).
Ethics Statement
All animal studies were performed according to the Regulations
for the Administration of Affairs Concerning Experiments
Animals (1988.11). The experimental protocols (Protocol
number: 20140623006) were approved and supervised by the
Institutional Animal Care and Use Committee (IACUC) of Jilin
University.
The source of O157:H7 strain EDL933 is ATCC 43895.
RESULT
BAI Protects Cells against Toxins
Released by EHEC Strain EDL933
In vitro protection assay showed that LDH released by cells
receiving culture supernatant from MMC-treated bacteria was
significantly higher than that from untreated cultures, indicating
that MMC induced the release of Stx toxins. Importantly,
inclusion of BAI (Figure 1A) in the culture supernatant protected
Hela cells from Stx-induced cell damage. Significant protection
was achieved when BAI was used at 9 µM and the maximal
protection was observed at 72 µM under our experimental
conditions (Figure 1B).
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FIGURE 1 | Baicalin protects cells against toxins released by EHEC strain EDL933. (A) Chemical structure of Baicalin. (B) Inhibition of cell death by baicalin.
Supernatant of EHEC EDL933 was added into Hela cells treated with indicated concentrations of baicalin for 36 h. Cell viability was evaluated by measuring
extracellular LDH 36 h after adding the supernatant. All data represent the mean and standard error of three independent experiments. ∗∗p < 0.01.
FIGURE 2 | Baicalin protects mice against lethal infection caused by EHEC strain EDL933. (A) Groups (n = 15) of mice infected with EDL933 via the oral
route together with MMC injection were treated with saline solution or with BAI 24 h post-infection. The survival of the animals was monitored for 10 days. (B) The
effects of BAI on body weight loss caused by sub-lethal doses of EDL933. Groups (n = 10) of mice infected with EDL933 as described in (A) were administered with
BAI or PBS. The body weight was monitored daily for 10 days. Similar results were obtained from more than three independent experiments.
BAI Protects Mice from EHEC Strain
EDL933 Infection
Mice protection effect of BAI was evaluated and a single challenge
of O157:H7 EDL933 without MMC caused no animal death
within 15 days. In contrast, a single inoculation of the bacteria
together with MMC caused 100% animal deaths within 8 days
(Figure 2A). In groups that received BAI, the death rate at day
8 was about 20% (Figure 2A), indicating that this compound
provides approximately 80% protection to O157:H7-infected
mice.
Body weights of the tested mice were monitored and our
results showed that infected mice not receiving BAI exhibited
decreased food and water intake; body weight loss became
apparent on day 4, and reached the lowest point at day 8
(Figure 2B). BAI treatment delayed the occurrence of body
weight loss for 48 h; Furthermore, the loss was significantly
less severe throughout the experiment duration (Figure 2B). As
expected, in line with their normal health status, the body weight
of mice receiving PBS increased throughout the experimental
duration (Figure 2B). Our choice of the 24-h treatment window
after infection was based on the comparison of several time points
including 12, 24, 36, and 48 (Figure 2A). The 24-h provided the
best protection and thus was used for all the relevant experiments.
Quantitative Analysis of Histopathology
Changes Showed Alleviated Pathologies
of BAI Treatment
Histopathology changes of renal glomerular degeneration
and renal tubule necrosis damages were quantified by a
histopathologist in a blind manner. Our results showed that
damages such as swelling, discoloration and necrosis were
severe in kidney tissues from infected mice not receiving BAI
(Figure 3A), while histopathological examination of kidney
tissue of BAI treatment group (Gu et al., 2016) indicated
that BAI treatment significantly reduced renal damage in mice
(Figure 3B).
Serological index and the release of pro-inflammatory of the
kidneys were tested. Six days after infection, the level of blood
urea nitrogen (BUN) in infected mice was 9.508 ± 0.414 mM;
BAI treatment reduced it to 6.143 ± 0.453 mM. In fact, the
level in treated mice was close to that of uninfected mice, which
was 4.675 ± 0.226 mM (Figure 4A). BAI treatment similarly
reduced the presence of creatinine (Cr) in the serum of infected
mice (Figure 4B). In agreement with these results, BAI treatment
significantly lowered the secretion of several cytokines such as
IL-1β, IL-6 and TNF-α associated with kidney damages caused
by O157:H7 infection (Figure 4C). Taken together, these results
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FIGURE 3 | Kidneys tissue and their histopathological examination by HE staining. (A) Comparison of kidneys tissue from differently treated mice. Note that
kidneys from BAI-treated mice exhibited lower pathological abnormalities. (B) Histopathological examination of kidney tissue by HE staining. PBS and MMC+BAI
group displayed standard kidney histopathology. a: complete glomerulus architecture, b: regular nuclear arrangement in renal tubule. EDL933 infection group space
between the glomerulus and Bowman’s capsule; b: loss of brush border in the renal tubule, along with cytoplasmic attending and loss of the epithelial cells; loss of
polarity of tubular cells and degeneration in the renal tubule. BAI administration improved kidney histopathology following EDL933 treatment. a: complete Bowman’s
capsule and glomerulus architecture; b: renal tubule with distributed brush border; Regular nuclear arrangement, and well-development renal tubule. Histopathology
scoring of renal glomerular degeneration and renal tubule necrosis by a veterinary pathologist: grade 0: no injury; grade 1: minimal injury with less than 10% of cells
exhibiting degeneration or necrosis; grade 2: mild injury involving 10–25% of cells; grade 3: moderate injury involving 25–40% of cells; grade 4: marked injury
involving 40–50% of cells; grade 5: severe injury involving greater than 50% of cells. N = 5, ∗∗p < 0.01 vs. EDL933 infection group.
FIGURE 4 | Baicalin alleviated the pathologies induced by EDL933 infection. (A,B) The effects of baicalin on blood urea nitrogen (BUN) (A) and creatinine (Cr)
(B). Induced by EDL933 infection. The blood of relevant mice groups was evaluated for BUN and Cr at 6 days after treatment. Each circle represents the BUN or Cr
level from one mouse, n = 5. (C) Baicalin reduced the production of several cytokines induced by EDL933. Kidney tissues from relevant mice were measured for
cytokines by ELISA. Note the reduction of cytokine production in infected mice treated with baicalin. ∗∗p < 0.01.
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indicate that BAI effectively protect the kidney from the damage
caused by O157:H7 infection.
DISCUSSION
Because of the high mortality and morbidity associated with
infections caused by O157:H7, extensive multidisciplinary efforts
have been invested to identify effective treatments. For example,
vaccines (Szu and Ahmed, 2014) and immunotherapies have been
described (Yamagami et al., 2001). The use of Stx receptor analogs
(Nishikawa et al., 2002, 2005) and antibodies specific to the toxins
has also been reported. A strategy that combined antibiotics
and antibody specific for the Stx appeared effective in in vitro
experiments (Skinner et al., 2015). The small molecule Retro-2cycl
that functions by inhibiting host retrograde trafficking is effective
against infections caused by the EHEC strain O104:H4 in a mouse
disease model (Secher et al., 2015).
Enterohemorrhagic serotype E. coli contains various virulence
factors, among which stx2 is the plays important role in the
pathogenicity of STEC O157 strain by neutralize the toxicity of
stx2, STEC O157: H7 becomes ordinary E. coli and clearance by
the organism (Nathan, 2002; Mombelli et al., 2011; Wiersinga,
2011). O104 may have the same mechanism as well. Although
the role of baicalin inhibiting the activity of rStx2 in vitro and
in vivo (Dong et al., 2015), the key virulence factor of EHEC
strains, was clarified in our previous study, the effect of baicalin
against EHEC infection was still unclear. There are several
virulence factors and other pathogenic factors secreted by EHEC
strains. Whether baicalin could still be a useful agent against
EHEC infection in such complicated condition was need to be
clarified. Furthermore, the toxin in our previous study was a
recombinant production, the activity, dosage and the infective
mode was completely different from natural infection by EHEC
strains. Thus, we designed experiments in this study to further
demonstrate the protective effect of baicalin against EHEC
infection. Our demonstration of the effectiveness of BAI against
O157:H7 infection in a post-infection manner, adds another
useful avenue to meet the challenges posed by Stx-producing
pathogens. Although the exact post-infection treatment window
for human remains to be determined, the 24-h window found
in mice should provide the reference for the time frame
necessary for good clinical outcomes, particularly for patients
suspected of consuming EHEC contaminated food. Comparing
to therapeutics such as toxin-specific antibodies and agents that
inhibit important host cellular processes, the advantages of BAI
lie in its low toxicity, high stability that allows convenient
transportation and storage. Like all compounds that proved to
be effective in animal model experiments, the next challenge is to
determine whether BAI is effective in the treatment of infections
caused by Stx-producing E. coli either by itself or in combination
with other agents.
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